Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/JPRN-jRCT2080221669
JPRN-jRCT2080221669UnknownPhase 3

An open-label long-term extension study to evaluate the safety and efficacy of venlafaxine ER in adult outpatients with major depressive disorder(B2411264)

Pfizer Japan Inc.0 sites50 target enrollmentStarted: December 8, 2011Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 3
Enrollment
50
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
>= 20age old to ot applicable (—)
Sex
All

Inclusion Criteria

  • •Outpatients who have completed 8 weeks double-blind study (B2411263), without major protocol violations or tolerability concerns in the opinion of the investigator.

Exclusion Criteria

  • •-Clinically important abnormalities on baseline (Week 8 of the double-blind study) physical examination, or any unresolved clinically significant abnormalities on electrocardiogram (ECG), laboratory test results, or vital signs recorded before Week 8 in the previous double-blind study.
  • •-Significant risk of suicide based on clinical judgment.
  • •-Use of prohibited treatments

Investigators

Similar Trials

Unknown
Phase 2
ong-term study of LCZ696 treatment in patients with essential hypertensio
JPRN-jRCT2080221787ovartis Pharma K.K.344
Active, not recruiting
Phase 1
An open label, long-term extension study to evaluate the safety and efficacy of CRN00808 in subjects with acromegaly (ACROBAT ADVANCE)MedDRA version: 20.0Level: PTClassification code: 10000599Term: Acromegaly Class: 100000004860Acromegaly
CTIS2024-511921-75-00Crinetics Pharmaceuticals Inc.31
Active, not recruiting
Phase 2
A 5-year study to test BI 655130 in patients with Generalized Pustular Psoriasis who took part in previous studies with BI 655130Generalized Pustular Psoriasis (GPP)
JPRN-jRCT2041210087Taguchi Aya131
Active, not recruiting
Phase 1
A 5-year study to test BI 655130 in patients with GeneralizedPustular Psoriasis who took part in previous studies with BI655130Generalized Pustular PsoriasisMedDRA version: 21.0Level: LLTClassification code 10037159Term: Psoriasis pustularSystem Organ Class: 100000004858
EUCTR2018-003080-56-ESBoehringer Ingelheim España S.A.150
Active, not recruiting
Phase 1
A 5-year study to test BI 655130 in patients with Generalized Pustular Psoriasis who took part in previous studies with BI 655130
EUCTR2018-003080-56-FRBoehringer Ingelheim France101